Olumiant · DIN 02480018 · 2mg · tablet
Limited Use — Reason for Use code 615, 734 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 615, 734 required
Write on scriptLU code 615, 734 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 615, 734
Reason for Use code 615
For the treatment of rheumatoid arthritis (RA) in combination with methotrexate in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:
A. i) Methotrexate (20mg/week) for at least 3 months, AND
ii) Leflunomide (20mg/day) for at least 3 months, in addition to
iii) An adequate trial of at least one combination of DMARDs for 3 months; OR
B. i) Methotrexate (20mg/week) for at least 3 months, AND
ii) Leflunomide in combination with methotrexate for at least 3 months; OR
C. i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)
In patients who demonstrated initial response to treatment (defined as an achievement of an American College of Rheumatology [ACR] improvement criteria of at least 20% [ACR20] at week 12), ongoing maintenance therapy is funded.
Maintenance/Renewal:
After 12 weeks of treatment, maintenance therapy is funded for patients who achieved an American College of Rheumatology (ACR) improvement criteria of at least 20% (ACR20) and a minimum of improvement in 2 swollen joints by week 12.
For renewals beyond 12 months, the patient must demonstrate objective evidence of preservation of treatment effect.
Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.
The recommended dosing regimen is 2mg administered once daily.
Baricitinib should not be used in combination with other Janus kinase (JAK) inhibitors or other biologic DMARDs to treat the patient's RA.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 734
Initiation criteria:
For the treatment of adult patients with severe alopecia areata (AA) who meet the following criteria:
1. Have a Severity of Alopecia Tool (SALT) score of 50 or above, and
2. Have experienced the current episode of AA for more than 6 months but less than 8 years.
The maximum duration of initial authorization is 36 weeks.
Renewal criteria:
For continuation of reimbursement, the patient must demonstrate beneficial clinical effect, defined as achieving a SALT score of 20 or less at 36 weeks after treatment initiation. Maintenance of a SALT score of 20 or less every 12 months thereafter is required for reimbursement renewal.
Dosing and prescribing:
The recommended dose is 2mg once daily. The maximum funded dose is 4mg once daily.
Baricitinib should be prescribed by a dermatologist with expertise managing patients with severe AA.
Baricitinib should not be used in combination with other JAK inhibitors, biologic immunomodulators, or systemic immunosuppressants.
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Olumiant · DIN 02480018
Manufacturer: Eli Lilly Canada Inc.; listing date 2021-08-31
Health Canada: Marketed since 2018-09-27 · brand OLUMIANT · ATC L04AF02 BARICITINIB · form Tablet · route Oral · ingredients BARICITINIB 2 MG · company Eli lilly canada inc · schedule Prescription
Olumiant: Formulary list price $59.4367/unit (unit not stated in source; not the patient's cost)
Ministry pays: $59.4367 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97056 · Verify on the e-Formulary ↗ (DIN 02480018)
Source record
DIN 02480018: Olumiant
Raw flags: sec12=Y, sec3=Y
Item: 924400011; group id 1043; item number 2395; lccId 00347; manufacturer id LIL
Source form: Tab; strength: 2mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $59.4367; ministry $59.4367
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02480018
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97056
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02480018
Shortage record checked 2026-09-13T08:10:21.292534+00:00